Source comparison
Side Effect Comparison by Route
Each route produces a distinct side effect profile. The differences trace directly to pharmacokinetics. Nausea Common (20-30%) Rare (<5%) Direct GI mucosal contact Diarrhea Common (first week) Rare Local intestinal effect Headache Uncommon (5-10%) More common
This comparison does not assign a generated winner or score.
- Each route produces a distinct side effect profile. The differences trace directly to pharmacokinetics.
- Nausea
- Common (20-30%)
- Rare (<5%)
- Direct GI mucosal contact
- Diarrhea
- Common (first week)
- Rare
- Local intestinal effect
- Headache
- Uncommon (5-10%)
- More common (15-20%)
- Faster vasodilation via NO system
- Injection-site pain
- N/A
- Common (25%)
- Needle trauma
- Injection-site redness
- Common (15-20%)
- Local immune response
- Dizziness
- Uncommon (10%)
- Higher peak plasma levels
- Bloating
- GI motility changes
- Insomnia
- Possible
- Dopamine modulation (both routes)
- Oral users experience more GI effects that resolve within 5-7 days. Injectable users deal with site reactions that recur with each injection but are typically mild. For capsule-specific details, see our BPC-157 capsule side effects guide. For headache concerns, see does BPC-157 cause headaches.
- Neither route has produced serious adverse events in published research (Sikiric et al., Pharmaceuticals, 2024).